Another randomized trial that evaluated the efficacy of triple therapy (Metformin, Rosiglitazone, and insulin) among 16 obese patients with T2DM reported that the triple therapy had a significant improvement in the HBA1c levels from the baseline (P = 0.004) [41]. This evidence concerns the gene INS and type 2 diabetes mellitus.